TCRCure Biopharma Ltd. aims to develop next generation cancer immunotherapies that control tumor progression, convert life-threatening cancers to manageable diseases, and eventually lead to cures. We are a leading international company focused on streamlined biotechnology development including high throughput antigen-specific TCR cloning, industry-scale virus production, T cell genetic engineering, and immune cell manufacturing.
TCRCure has established two GMP-level manufacturing facilities in Los Angeles and Guangzhou, as well as two research and development, translational medicine centers in North Carolina and Chongqing.
As of 2019, TCRCure has over 90 employees, with more than 40% of them being Ph.Ds. The company has several pipelines of TCR-T cell therapy products for solid tumors including cervical cancer, nasopharyngeal carcinoma，head and neck cancer，lung squamous carcinoma, colorectal cancer, ovarian cancer, multiple myeloma, and brain cancer. TCRCure has started clinical trials and translational medicine research in coordination with the top hospitals in Chongqing, Chengdu, and Guangzhou, China.
In addition, TCRCure has solid clinical data and robust pipelines for viral vector and T cell manufacturing. The company has obtained technology authorization, commissioned R&D contracts, received production orders from pharmaceutical factories, and has attracted millions of USD in funding from top investment companies.